Literature DB >> 11037972

Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes.

M Dettke1, G Pálfi, H Loibner.   

Abstract

The expression of the difucosyl-lactosamine type 2 oligosaccharide Lewis Y (LeY) on peripheral blood cells was investigated. As assessed by the reactivity with the mouse anti-LeY monoclonal antibody (mAb) ABL 364 among circulating blood cells, the expression of the LeY oligosaccharide was uniquely restricted to granulocytes. Although the density of LeY expressed on resting granulocytes was weak, in vitro activation of granulocytes with fMLP induced a rapid and pronounced increase in granulocyte LeY expression. Analysis of CEA-related glycoproteins immunoprecipitated with anti-CD66 mAbs followed by immunoblotting with mAb ABL 364 showed that granulocyte LeY is attached to members of the CD66 cluster, in particular to the 160/90 kD glycoprotein recognized by anti-CD66 mAb CBL/gran 10. The activation-associated increase in LeY attached to CD66 adhesion molecules implicates a role of the LeY determinant in the cytoadhesive properties of granulocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11037972

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  26 in total

1.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.

Authors:  Robert Brodzik; Magdalena Glogowska; Katarzyna Bandurska; Monika Okulicz; Deepali Deka; Kisung Ko; Joke van der Linden; Jeanette H W Leusen; Natalia Pogrebnyak; Maxim Golovkin; Zenon Steplewski; Hilary Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-23       Impact factor: 11.205

2.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Authors:  Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Authors:  Yuelong Ma; Claudia M Kowolik; Piotr M Swiderski; Marcin Kortylewski; Hua Yu; David A Horne; Richard Jove; Otavia L Caballero; Andrew J G Simpson; Fook-Thean Lee; Vinochani Pillay; Andrew M Scott
Journal:  ACS Chem Biol       Date:  2011-07-26       Impact factor: 5.100

Review 4.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

5.  Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors.

Authors:  Feifei Li; Bei Lin; Yingying Hao; Yan Li; Juanjuan Liu; Jianping Cong; Liancheng Zhu; Qing Liu; Shulan Zhang
Journal:  Int J Mol Sci       Date:  2010-09-29       Impact factor: 5.923

6.  Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.

Authors:  Rebecca A Herbertson; Niall C Tebbutt; Fook-Thean Lee; David J MacFarlane; Bridget Chappell; Noel Micallef; Sze-Ting Lee; Timothy Saunder; Wendie Hopkins; Fiona E Smyth; David K Wyld; John Bellen; Daryl S Sonnichsen; Martin W Brechbiel; Carmel Murone; Andrew M Scott
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

7.  Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response.

Authors:  Chung-Sheng Shi; Guey-Yueh Shi; Hsi-Min Hsiao; Shi-Ming Hsiao; Yuan-Chung Kao; Kuan-Lin Kuo; Chih-Yuan Ma; Cheng-Hsiang Kuo; Bi-Ing Chang; Chuan-Fa Chang; Chun-Hung Lin; Chi-Huey Wong; Hua-Lin Wu
Journal:  Blood       Date:  2008-08-18       Impact factor: 22.113

8.  Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis.

Authors:  Mingzi Tan; Liancheng Zhu; Huiyu Zhuang; Yingying Hao; Song Gao; Shuice Liu; Qing Liu; Dawo Liu; Juanjuan Liu; Bei Lin
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

9.  Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).

Authors:  Marina Isla Larrain; Sandra Demichelis; Marina Crespo; Ezequiel Lacunza; Alberto Barbera; Aldo Cretón; Francisco Terrier; Amada Segal-Eiras; María Virginia Croce
Journal:  J Exp Clin Cancer Res       Date:  2009-08-28

10.  Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.

Authors:  Juanjuan Liu; Bei Lin; Yingying Hao; Yue Qi; Liancheng Zhu; Feifei Li; Dawo Liu; Jianping Cong; Shulan Zhang; Masao Iwamori
Journal:  J Exp Clin Cancer Res       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.